RANI THERAPEUTICS HOLDINGS INC. - CLASS A COMMON

Rani Therapeutics to Participate in Upcoming Investor Conferences

07 نوفمبر 2024 16:05:02 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

17 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

15 أكتوبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

08 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics to Participate in September Investor Conferences

03 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

06 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics to Participate in August Investor Conferences

29 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

22 يوليو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

24 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics to Participate in May Investor Conferences

14 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

09 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

06 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

20 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

15 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

05 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

14 ديسمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

08 نوفمبر 2023 16:05:02 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results

01 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

25 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

19 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire